Chemo Pharma Laboratories Ltd
The Chemo Pharma Laboratories Limited was established in 1942 and was making Pharmaceuticals and bulk drugs. However due to increased competition, Company disposed the business. Company is in advanced stage of negotiation to diversify and take over a sick company[1]
- Market Cap ₹ 19.7 Cr.
- Current Price ₹ 131
- High / Low ₹ 154 / 55.1
- Stock P/E 179
- Book Value ₹ 24.5
- Dividend Yield 0.00 %
- ROCE %
- ROE %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
Cons
- Stock is trading at 5.37 times its book value
- Promoter holding is low: 27.9%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2016 | |
|---|---|
| 0.00 | |
| 1.84 | |
| Operating Profit | -1.84 |
| OPM % | |
| 0.49 | |
| Interest | 0.00 |
| Depreciation | 0.00 |
| Profit before tax | -1.35 |
| Tax % | 7.41% |
| -1.45 | |
| EPS in Rs | -9.67 |
| Dividend Payout % | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 22% |
| 5 Years: | 86% |
| 3 Years: | 46% |
| 1 Year: | 59% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2016 | |
|---|---|
| Equity Capital | 1.50 |
| Reserves | 2.17 |
| 0.00 | |
| 0.20 | |
| Total Liabilities | 3.87 |
| 0.00 | |
| CWIP | 0.00 |
| Investments | 0.02 |
| 3.85 | |
| Total Assets | 3.87 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2016 | |
|---|---|
| -2.09 | |
| 2.15 | |
| 0.00 | |
| Net Cash Flow | 0.06 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2016 | |
|---|---|
| Debtor Days | |
| Inventory Days | |
| Days Payable | |
| Cash Conversion Cycle | |
| Working Capital Days | |
| ROCE % |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Change in Management
16 Apr - Major board and management reshuffle, including CEO and CFO appointments and resignations.
-
Board Meeting Outcome for OUTCOME OF THE BOARD MEETING HELD ON WEDNESDAY, APRIL 16, 2025
16 Apr - Major board and management reshuffle, including new CEO, CFO, and resignations of key directors.
-
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
16 Apr - Company not classified as Large Corporate under SEBI circular.
-
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
15 Apr - Disclosure of non-applicability of SEBI large corporate debt rules.
-
Declaration Of Non-Applicability Of Regulation 23(9) Of SEBI (LODR) Regulation, 2015
15 Apr - Non-applicability of SEBI related party disclosure due to company size.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Background[1]
The Chemo Pharma Laboratories Limited was established in 1942 and has been making pharmaceuticals and diversified into bulk drugs. However due to increase in competition and flow of new drugs, Company disposes their business and pay all its liabilities and dues. Presently the Company has its own cash resource, with this the Company is proposing to diversify and to take over Sick Company which has excellent future potential. The Company is in advance in the negotiation to some other company and soon rehab to acquire business in Power and Chemicals.